Physician profile
Michael Warren
NPI 1114329810
$4,321.03
in general payments reported to CMS, 2019-2025
26 companies · $836 in 2025
The $836 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $571 · 2023: $2,018 · 2024: $654 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,369 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,368.53 |
| Education | $139.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,091.69 | 2021-2025 | |
| Janssen Biotech, INC. | $575.22 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Leo Pharma INC. | $436.65 | 2021-2025 | Adbry |
| Lilly USA, LLC | $408.04 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $308.85 | 2023-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $273.98 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $206.83 | 2021-2024 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $157.54 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $134.89 | 2023-2024 | Libtayo, Dupixent |
| Arcutis Biotherapeutics, INC. | $126.02 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $85.53 | 2021-2025 | Nemluvio |
| Biofrontera INC. | $84.86 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Journey Medical Corporation | $76.75 | 2024 | |
| Almirall LLC | $57.77 | 2022-2025 | Seysara |
| Incyte Corporation | $54.53 | 2022-2023 | Opzelura |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $46.58 | 2023 | Vtama |
| Fresenius Kabi USA, LLC | $25.77 | 2023 | |
| Vyne Pharmaceuticals INC. | $23.36 | 2021 | |
| Amgen INC. | $22.37 | 2025 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.92 | 2024 | Cyltezo |
| Novartis Pharmaceuticals Corporation | $19.40 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.81 | 2023 | Targretin, Siliq |
| E.R. Squibb & Sons, L.L.C. | $18.42 | 2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $18.02 | 2024 | Tremfya |
| Organon LLC | $17.30 | 2025 | Vtama |
| Biodermis LLC | $11.93 | 2025 | Biocorneum, Pro-Sil, Epi-Derm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.